Nkarta
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Nkarta and other ETFs, options, and stocks.About NKTX
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells.
CEOPaul J. Hastings
CEOPaul J. Hastings
Employees157
Employees157
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2005
Founded2005
Employees157
Employees157
NKTX Key Statistics
Market cap122.76M
Market cap122.76M
Price-Earnings ratio-1.15
Price-Earnings ratio-1.15
Dividend yield—
Dividend yield—
Average volume509.76K
Average volume509.76K
High today$1.83
High today$1.83
Low today$1.72
Low today$1.72
Open price$1.73
Open price$1.73
Volume330.13K
Volume330.13K
52 Week high$8.23
52 Week high$8.23
52 Week low$1.31
52 Week low$1.31
Analyst ratings
86%
of 7 ratingsBuy
85.7%
Hold
14.3%
Sell
0%
People also own
Based on the portfolios of people who own NKTX. This list is generated using Robinhood data, and it’s not a recommendation.